Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
FSGRX Franklin Small Cap Growth Fund Class A
IVR-B Invesco Mortgage Capital Inc
EWBC East West Bancorp Inc
RVNC Revance Therapeutics Inc
ZFGN Zafgen Inc
SFOR StrikeForce Technologies Inc
SPLV Invesco S&P 500® Low Volatility ETF
USMV iShares Edge MSCI Min Vol USA ETF
HULYX Hawaiian Tax-Free Trust Class Y
Go

Financials : Banks | Large Cap ValueCompany profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Closing Price
$26.47
Day's Change
-0.72 (-2.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
27.22
Day's Low
26.26
Volume
(Heavy Day)
Volume:
81,898,762

10-day average volume:
63,463,078
81,898,762

Robbins Arroyo LLP: Corbus Pharmaceuticals Holdings, Inc. (CRBP) Sued for Misleading Shareholders

6:39 pm ET June 10, 2019 (BusinessWire) Print

Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between November 14, 2016 and February 28, 2019. Corbus purports to be a pharmaceutical company focused on the development and commercialization of novel therapies to treat inflammatory and fibrotic diseases.

View this information on the law firm's Shareholder Rights Blog: https://www.robbinsarroyo.com/corbus-pharmaceuticals-holdings-jun-19/

Corbus Accused of Faking Clinical Results for Lenabasum

According to the complaint, since 2016, Corbus falsely assured investors with reports of positive clinical data in its studies for Lenabasum. Then, on February 28, 2019, a SeekingAlpha article was published denouncing the company's results by stating that Lenabasum's "Phase 2 trial in SSc was a massive failure." When the truth about Lenabasum was revealed, Corbus' stock fell almost 16% on February 28, 2019. The stock still trades below its class period high.

Corbus Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leo Kandinov at (800) 350-6003, LKandinov@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005793/en/

SOURCE: Robbins Arroyo LLP

Leo KandinovRobbins Arroyo LLP5040 Shoreham PlaceSan Diego, CA 92122LKandinov@robbinsarroyo.com(619) 525-3990 or Toll Free (800) 350-6003www.robbinsarroyo.com

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.